Insertions in the human immunodeficiency virus type 1 protease and reverse transcriptase genes: Clinical impact and molecular mechanisms

Antimicrobial Agents and Chemotherapy

Volumn 49, Issue 7, 2005, Pages 2575-2582

  Winters, Mark A ^a,b   Merigan, Thomas C ^a  

^a STANFORD UNIVERSITY   (United States)

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; ANTIRETROVIRUS AGENT; DIDANOSINE; EFAVIRENZ; HYDROXYUREA; LAMIVUDINE; NEVIRAPINE; PROTEINASE; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; TENOFOVIR; UNCLASSIFIED DRUG; VIRUS FUSION INHIBITOR; ZALCITABINE; ZIDOVUDINE;

CODON; DRUG EFFICACY; DRUG SENSITIVITY; GENE DELETION; GENE INSERTION; GENE MUTATION; GENETIC VARIABILITY; GEOGRAPHIC DISTRIBUTION; GP41 GENE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; NONHUMAN; PR GENE; PRIORITY JOURNAL; RT GENE; SHORT SURVEY; SITE DIRECTED MUTAGENESIS; STRAIN DIFFERENCE; TREATMENT FAILURE; VIRUS GENE; VIRUS RESISTANCE;

AMINO ACID SUBSTITUTION; ANTI-HIV AGENTS; DRUG RESISTANCE, VIRAL; HIV INFECTIONS; HIV PROTEASE; HIV-1; HIV-1 REVERSE TRANSCRIPTASE; HUMANS; MICROBIAL SENSITIVITY TESTS; MODELS, MOLECULAR; REVERSE TRANSCRIPTASE INHIBITORS; TREATMENT FAILURE;

EID: 21444441862     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.49.7.2575-2582.2005     Document Type: Short Survey

References (73)

1. Alexander, L., M. J. Aquino-DeJesus, M. Chan, and W. A. Andiman. 2002. Inhibition of human immunodeficiency virus type 1 (HIV-1) replication by a two-amino-acid insertion in HIV-1 Vif from a nonprogressing mother and child. J. Virol. 76:10533-10539.
2. Bally, F., R. Martinez, S. Peters, P. Sudre, and A. Telenti. 2000. Polymorphism of HIV type 1 gag p7/p1 and p1/p6 cleavage sites: clinical significance and implications for resistance to protease inhibitors. AIDS Res. Hum. Retrovir. 16:1209-1213.
3. Bebenek, K., J. Abbotts, S. H. Wilson, and T. A. Kunkel. 1993. Error-prone polymerization by HIV-1 reverse transcriptase. Contribution of template-primer misalignment, miscoding, and termination probability to mutational hot spots. J. Biol. Chem. 268:10324-10334.
4. Bonfanti, P., L. Valsecchi, F. Parazzini, S. Carradori, L. Pusteria, P. Fortuna, L. Timillero, F. Alessi, G. Ghiselli, A. Gabbuti, E. Di Cintio, C. Martinelli, I. Faggion, S. Landonio, T. Quirino, et al. 2000. Incidence of adverse reactions in HIV patients treated with protease inhibitors: a cohort study. AIDS 23:236-245.
5. Boyer, P. L., T. Imamichi, S. G. Sarafianos, E. Arnold, and S. H. Hughes. 2004. Effects of the delta67 complex of mutations in human immunodeficiency virus type 1 reverse transcriptase on nucleoside analog excision. J. Virol. 78:9987-9997.
6. Boyer, P. L., J. Lisziewicz, F. Lori, and S. H. Hughes. 1999. Analysis of amino insertion mutations in the fingers subdomain of HIV-1 reverse transcriptase. J. Mol. Biol. 286:995-1008.
7. Boyer, P. L., S. G. Sarafianos, E. Arnold, and S. H. Hughes. 2002. Nucleoside analog resistance caused by insertions in the fingers of human immunodeficiency virus type 1 reverse transcriptase involves ATP-mediated excision. J. Virol. 76:9143-9151.
8. Briones, C., A. Mas, G. Gomez-Mariano, C. Altisent, L. Menendez-Arias, V. Soriano, and E. Domingo. 2000. Dynamics of dominance of a dipeptide insertion in reverse transcriptase of HIV-1 from patients subjected to prolonged therapy. Virus Res. 66:13-26.
9. Briones, C., and V. Soriano. 1999. Different outcome in the first two patients with an HIV-1 multinucleoside drug-resistant T69SSS insertion in Spain. Antivir. Ther. 4:125-127.
10. Daar, E. S., S. D. Frost, J. K. Wong, N. S. Hellmann, T. Wrin, C. J. Petropoulos, D. D. Richman, J. A. Pitt, S. J. Little, and A. J. Leigh Brown. 2002. 9th Conf. Retrovir. Opportunistic Infect.
11. 10a. Das, K., S. Sarafianos, J. Ding, S. Tuske, A. D. Cark, Jr., P. L. Boyer, P. Clark, S. Hughes, and E. Arnold. 2002. Coming of age: a decade of HIV-1 reverse transcripase structures. Int. Antivir. News 9:177-180.
12. De Antoni, A., A. Foli, J. Lisziewicz, and F. Lori. 1997. Mutations in the pol gene of human immunodeficiency virus type 1 in infected patients receiving didanosine and hydroxyurea combination therapy. J. Infect. Dis. 176:899-903.
13. de Jong, J. J., J. Goudsmit, V. V. Lukashov, M. E. Hillebrand, E. Baan, R. Huismans, S. A. Danner, J. H. ten Veen, F. de Wolf, and S. Jurriaans. 1999. Insertion of two amino acids combined with changes in reverse transcriptase containing tyrosine-215 of HIV 1 resistant to multiple nucleoside analogs. AIDS 13:75-80.
14. Doyon, L., G. Croteau, D. Thibeault, F. Poulin, L. Pilote, and D. Lamarre. 1996. Second locus involved in human immunodeficiency virus type 1 resistance to protease inhibitors. J. Virol. 70:3763-3769.
15. Fikkert, V., B. Van Maele, J. Vercammen, A. Hantson, B. Van Remoortel, M. Michiels, C. Gurnari, C. Pannecouque, M. De Maeyer, Y. Engelborghs, E. De Clercq, Z. Debyser, and M. Witvrouw. 2003. Development of resistance against diketo derivatives of human immunodeficiency virus type 1 by progressive accumulation of integrase mutations. J. Virol. 77:11459-11470.
16. Goldschmidt, V., and R. Marquet. 2004. Primer unblocking by HIV-1 reverse transcriptase and resistance to nucleoside RT inhibitors (NRTIs). Int. J. Biochem. Cell Biol. 36:1687-1705.
17. Grant, R. M., J. O. Kahn, T. Wrin, B. Drews, J. Javier, M. Webb, C. J. Petropoulos, and F. M. Hecht. 2001. HIV-1 with an insertion in protease is drug-susceptible, replication-competent, and transmissible. Antivir. Ther. 6:44.
18. Greenberg, M. L., and N. Cammack. 2004. Resistance to enfuvirtide, the first HIV fusion inhibitor. J. Antimicrob. Chemother. 54:333-340.
19. Grossman, Z., K. Sugarman, D. Auerbuch, V. Istomin, H. Rudich, S. Maayan, K. Rizenfeld, I. Levi, P. Shahar, M. Chowers, M. Burke, E. Mendelson, F. Schlaesser, S. Pollack, Z. Bentwich, and J. M. Schapiro. 2002. Reverse transcriptase T69 6-bp insertion and multi-class resistance within a population of nucleoside reverse transcriptase inhibitor-treated subtype C patients. Antivir. Ther. 7:S148.
20. Harrigan, P. R., M. D. Miller, P. McKenna, Z. L. Brumme, and B. A. Larder. 2002. Phenotypic susceptibilities to tenofovir in a large panel of clinically derived human immunodeficiency virus type 1 isolates. Antimicrob. Agents Chemother. 46:1067-1072.
21. Harrison, G. P., M. S. Mayo, E. Hunter, and A. M. Lever. 1998. Pausing of reverse transcriptase on retroviral RNA templates is influenced by secondary structures both 5′ and 3′ of the catalytic site. Nucleic Acids Res. 26:3433-3442.
22. Haubrich, R. H., C. A. Kemper, N. S. Hellmann, P. H. Keiser, M. D. Witt, D. N. Forthal, J. Leedom, M. Leibowitz, J. M. Whitcomb, D. Richman, and J. A. McCutchan. 2002. The clinical relevance of non-nucleoside reverse transcriptase inhibitor hypersusceptibility: a prospective cohort analysis. AIDS 16;F33-F40.
23. Hazuda, D. J., N. J. Anthony, R. P. Gomez, S. M. Jolly, J. S. Wai, L. Zhuang, T. E. Fisher, M. Embrey, J. P. Guare, Jr., M. S. Egbertson, J. P. Vacca, J. R. Huff, P. J. Felock, M. V. Witmel, K. A. Stillmock, R. Danovich, J. Grobler, M. D. Miller, A. S. Espeseth, L. Jin, I. W. Chen, J. H. Lin, K. Kassahun, J. D. Ellis, B. K. Wong, W. Xu, P. G. Pearson, W. A. Schleif, R. Cortese, E. Emini, V. Summa, M. K. Holloway, and S. D. Young. 2004. A naphthyridine carboxamide provides evidence for discordant resistance between mechanistically identical inhibitors of HIV-1 integrase. Proc. Natl. Acad. Sci. USA 101:11233-11238.
24. Hiehenthal-Millow, K., and F. Kirchhoff. 2002. The most frequent naturally occurring length polymorphism in the HIV-1 LTR has little effect on proviral transcription and viral replication. Virology 292:169-175.
25. Hirsch, M. S., F. Brun-Vezinet, B. Clotet, B. Conway, D. R. Kuritzkes, R. T. D'Aquila, L. M. Demeter, S. M. Hammer, V. A. Johnson, C. Loveday, J. W. Mellors, D. M. Jacobsen, and D. D. Richman. 2003. Antiretroviral drug resistance testing in adults infected with human immunodeficiency virus type 1: 2003 recommendations of and International AIDS Society-USA Panel. Clin. Infect. Dis. 37:113-128.
26. Ibe, S., N. Shibata, M. Utsumi, and T. Kaneda. 2003. Selection of human immunodeficiency virus type 1 variants with an insertion mutation in the p6(gag) and p6(pol) genes under highly active antiretroviral therapy. Microbiol. Immunol. 47:71-79.
27. Imamichi, T., M. A. Murphy, H. Imamichi, and H. C. Lane. 2001. Amino acid deletion at codon 67 and Thr-to-Gly change at codon 69 of human immunodeficiency virus type 1 reverse transcriptase confer novel drug resistance profiles. J. Virol. 75:3988-3992.
28. Imamichi, T., T. Sinha, H. Imamichi, Y. M. Zhang, J. A. Metcalf, J. Falloon, and H. C. Lane. 2000. High-level resistance to 3′-azido-3′- deoxythimidine due to a deletion in the reverse transcriptase gene of human immunodeficiency virus type 1. J. Virol. 74:1023-1028.
29. Jansson, M., E. Backstrom, G. Scarlatti, A. Bjorndal, S. Matsuda, P. Rossi, J. Albert, and H. Wigzell. 2001. Length variation of glycoprotein 120 V2 region in relation to biological phenotypes and coreceptor usage of primary HIV type 1 isolates. AIDS Res. Hum. Retrovir. 17:1405-1414.
30. Kagan, R., M. Winters, T. Merigan, and P. Heseltine. 2004. HIV type 1 genotypic resistance in a clinical database correlates with antiretroviral utilization. AIDS Res. Hum. Retrovir. 20:1-9.
31. Kim, E. Y., M. A. Winters, R. M. Kagan, and T. C. Merigan. 2001. Functional correlates of insertion mutations in the protease gene of human immunodeficiency virus type 1 isolates from patients. J. Virol. 75:11227-11233.
32. Larder Ba, B. S., S. D. Kemp, K. Hertogs, R. L. Desmet, V. Miller, M. Stunner, S. Staszewski, J. Ren, D. D. Stammers, D. I. Stuart, and R. Pauwels. 1999. A family of insertion mutations between codons 67 and 70 of human immunodeficiency virus type 1 reverse transcriptase confer multinucleoside analog resistance. Antimicrob. Agents Chemother. 43:1961-1967.
33. Lee, D. J., and W. E. Robinson, Jr. 2004. Human immunodeficiency virus type 1 (HIV-1) integrase: resistance to diketo acid integrase inhibitors impairs HIV-1 replication and integration and confers cross-resistance to L-chicoric acid. J. Virol. 78:5835-5847.
34. Lennerstrand, J., D. K. Stammers, and B. A. Larder. 2001. Biochemical mechanism of human immunodeficiency virus type 1 reverse transcriptase resistance to stavudine. Antimicrob. Agents Chemother. 45:2144-2146.
35. Lobato, R. L., E. Y. Kim, R. M. Kagan, and T. C. Merigan. 2002. Genotypic and phenotypic analysis of a novel 15-base insertion occurring between codons 69 and 70 of HIV type 1 reverse transcriptase. AIDS Res. Hum. Retrovir. 18:733-736.
36. Lukashov, V. V., R. Huismans, M. F. Jebbink, S. A. Danner, R. J. de Boer, and J. Goudsmit. 2001. Selection by AZT and rapid replacement in the absence of drugs of HIV type 1 resistant to multiple nucleoside analogs. AIDS Res. Hum. Retrovir. 17:807-818.
37. Maguire, M. F., R. Guinea, P. Griffin, S. Macmanus, R. C. Elston, J. Wolfram, N. Richards, M. H. Hanlon, D. J. Porter, T. Wrin, N. Parkin, M. Tisdale, E. Furfine, C. Petropoulos, B. W. Snowden, and J. P. Kleim. 2002. Changes in human immunodeficiency virus type 1 Gag at positions L449 and P453 are linked to I50V protease mutants in vivo and cause reduction of sensitivity to amprenavir and improved viral fitness in vitro. J. Virol. 76:7398-7406.
38. Marchadier, E., C. Domingo, L. Escaut, D. Vittecoq, J. Y. Loiotier, A. Beyou, and E. Dussaix. 2000. New insertin in the HIV-1 protease gene associated with indinavir resistance. Antivir. Ther. 5:44-45.
39. Mas, A., M. Parera, C. Briones, V. Soriano, M. A. Martinez, E. Domingo, and L. Menedez-Arias. 2000. Role of a dipeptide insertion between codons 69 and 70 of HIV-1 reverse transcriptase in the mechanism of AZT resistance. EMBO J. 19:5752-5761.
40. Masquelier, B., E. Race, C. Tamalet, D. Descamps, J. Izopet, C. Buffet-Janvresse, A. Ruffault, A. S. Mohammed, J. Cottalorda, A. Schmuck, V. Calvez, E. Dam, H. Fleury, and F. Brun-Vezinet. 2001. Genotypic and phenotypic resistance patterns of human immunodeficiency virus type 1 variants with insertions or deletions in the reverse transcriptase (RT): multicenter study of patients treated with RT inhibitors. Antimicrob. Agents Chemother. 45:1836-1842.
41. Matamoros, T., S. Franco, B. M. Vazquez-Alvarez, A. Mas, M. A. Martinez, and L. Menendez-Arias. 2004. Molecular determinants of multi-nucleoside analogue resistance in HIV-1 reverse transcriptases containing a dipeptide insertion in the fingers subdomain: effect of mutations D67N and T215Y on removal of thymidine nucleotide analogues from blocked DNA primers. J. Biol. Chem. 279:24569-24577. Epub 25 March 2004.
42. Meyer, P. R., J. Lennerstrand, S. E. Matsuura, B. A. Larder, and W. A. Scott. 2003. Effects of dipeptide insertions between codons 69 and 70 of human immunodeficiency virus type 1 reverse transcriptase on primer unblocking, deoxynucleoside triphosphate inhibition, and DNA chain elongation. J. Virol. 77:3871-3877.
43. Moreno, S., J. L. Casado, M. J. Perez-Elias, F. Dronda, A. Antela, A. Moreno, and C. Gutierrez. 2003. Hypersusceptibility to non-nucleoside reverse transcriptase inhibitors in HIV-1. AIDS 17:1413-1414.
44. Myint, L., M. Matsuda, Z. Matsuda, Y. Yokomaku, T. Chiba, A. Okano, K. Yamada, and W. Sugiura. 2004. Gag non-cleavage site mutations contribute to full recovery of viral fitness in protease inhibitor-resistant human immunodeficiency virus type 1. Antimicrob. Agents Chemother. 48:444-452.
45. Paolucci, S., F. Baldanti, G. Maga, R. Cancio, M. Zazzi, M. Zavattoni, A. Chiesa, S. Spadari, and G. Gerna. 2004. Gln145Met/Leu changes in human immunodeficiency virus type 1 reverse transcriptase confer resistance to nucleoside and nonnucleoside analogs and impair virus replication. Antimicrob. Agents Chemother. 48:4611-4617.
46. Peters, S., M. Munoz, S. Yerly, V. Sanchez-Merino, C. Lopez-Galindez, L. Perrin, B. Larder, D. Cmarko, S. Fakan, P. Meylan, and A. Telenti. 2001. Resistance to nucleoside analog reverse transcriptase inhibitors mediated by human immunodeficiency virus type 1 p6 protein. J. Virol. 75:9644-9653.
47. Pettit, S. C., G. J. Henderson, C. A. Schiffer, and R. Swanstrom. 2002. Replacement of the P1 amino acid of human immunodeficiency virus type 1 Gag processing sites can inhibit or enhance the rate of cleavage by the viral protease. J. Virol. 76:10226-10233.
48. Prado, J. G., S. Franco, T. Matamoros, L. Ruiz, B. Clotet, L. Menendez-Arias, M. A. Martinez, and J. Martinez-Picado. 2004. Relative replication fitness of multi-nucleoside analogue-resistant HIV-1 strains bearing a dipeptide insertion in the fingers subdomain of the reverse transcriptase and mutations at codons 67 and 215. Virology 326:103-112.
49. Quinones-Mateu, M. E., M. Tadele, M. Parera, A. Mas, J. Weber, H. R. Rangel, B. Chakraborty, B. Clotet, E. Domingo, L. Menendez-Arias, and M. A. Martinez. 2002. Insertions in the reverse transcriptase increase both drug resistance and viral fitness in a human immunodeficiency virus type 1 isolate harboring the multi-nucleoside reverse transcriptase inhibitor resistance 69 insertion complex mutation. J. Virol. 76:10546-10552.
50. Rambaut, A., D. Posada, K. A. Crandall, and E. C. Holmes. 2004. The causes and consequences of HIV evolution. Nat. Rev. Genet. 5:52-61.
51. Rhee, S. Y., M. J. Gonzales, R. Kantor, B. J. Betts, J. Ravela, and R. W. Shafer. 2003. Human immunodeficiency virus reverse transcriptase and protease sequence database. Nucleic Acids Res. 31:298-303.
52. Ross, L., M. Johnson, R. G. Ferris, S. A. Short, L. R. Boone, T. E. Melby, R. Lanier, M. Shaefer, and M. St. Clair. 2000. Deletions in the beta3-beta4 hairpin loop of HIV-1 reverse transcriptase are observed in HIV-1 isolated from subjects during long-term antiretroviral therapy. J. Hum. Virol. 3:144-149.
53. Schinazi, R. F., B. A. Larder, and J. W. Mellors. 2000. Mutations in retroviral genes associated with drug resistance: 2000-2001 update. Int. Antivir. News 8:65-91.
54. Schneider, V., J. Legoff, L. Belec, N. Delphin, C. Dutreuil, A. Kara-Mostefa, W. Rozenbaum, and J. C. Nicolas. 2004. Peptide insertions in reverse transcriptase pol gene of human immunodeficiency virus type 1 as a rare cause of persistent antiretroviral therapeutic failure. Clin. Microbiol. Infect. 10:127-136.
55. Selmi, B., J. Deval, J. Boretto, and B. Canard. 2003. Nucleotide analogue binding, catalysis and primer unblocking in the mechanisms of HIV-1 reverse transcriptase-mediated resistance to nucleoside analogues. Antivir. Ther. 8:143-154.
56. Shulman, N., A. R. Zolopa, D. Passaro, R. W. Shafer, W. Huang, D. Kalzenstein, D. M. Israelski, N. Hellmann, C. Petropoulos, and J. Whitcomb. 2001. Phenotypic hypersusceptibility to non-nucleoside reverse transcriptase inhibitors in treatment-experienced HIV-infected patients: impact on virological response to efavirenz-based therapy. AIDS 15:1125-1132.
57. Sturmer, M., S. Staszewski, H. W. Doerr, and K. Hertogs. 2003. A 6-base pair insertion in the protease gene of HIV type 1 detected in a protease inhibitor-naive patient is not associated with indinavir treatment failure. AIDS Res. Hum. Retrovir. 19:967-968.
58. Sugiura, W., M. Matsuda, Z. Matsuda, H. Abumi, A. Okano, T. Oishi, K. Moriya, Y. Yamamoto, K. Fukutake, J. Mimaya, A. Ajisawa, M. Taki, K. Yamada, and Y. Nagai. 1999. Identification of insertion mutations in HIV-1 reverse transcriptase causing multiple drug resistance to nucleoside analogue reverse transcriptase inhibitors. J. Hum. Virol. 2:146-153.
59. Suzuki, K., G. R. Kaufmann, M. Mukaide, P. Cunningham, C. Harris, L. Leas, M. Kondo, M. Imai, S. L. Pett, R. Finlayson, J. Zaunders, A. Kelleher, and D. A. Cooper. 2001. Novel deletion of HIV type 1 reverse transcriptase residue 69 conferring selective high-level resistance to nevirapine. AIDS Res. Hum. Retrovir. 17:1293-1296.
60. Tamalet, C., J. Izopet, N. Koch, J. Fantini, and N. Yahi. 1998. Stable rearrangements of the beta3-beta4 hairpin loop of HIV-1 reverse transcriptase in plasma viruses from patients receiving combination therapy. AIDS 12:F161-F166.
61. Tamalet, C., N. Yahi, C. Tourres, P. Colson, A. M. Quinson, I. Poizot-Martin, C. Dhiver, and J. Fantini. 2000. Multidrug resistance genotypes (insertions in the beta3-beta4 finger subdomain and MDR mutations) of HIV-1 reverse transcriptase from extensively treated patients: incidence and association with other resistance mutations. Virology 270:310-316.
62. Tamiya, S., S. Mardy, M. F. Kavlick, K. Yoshimura, and H. Mistuya. 2004. Amino acid insertions near Gag cleavage sites restore the otherwise compromised replication of human immunodeficiency virus type 1 variants resistant to protease inhibitors. J. Virol. 78:12030-12040.
63. van der Hoek, L., N. Back, M. F. Jebbink, A. de Ronde, M. Bakker, S. Jurriaans, P. Reiss, N. Parkin, and B. Berkhout. 2005. Increased multinucleoside drug resistance and decreased replicative capacity of a human immunodeficiency virus type 1 variant with an 8-amino-acid insert in the reverse transcriptase. J. Virol. 79:3536-3543.
64. Van Vaerenbergh, K., K. Van Laethem, J. Albert, C. A. Boucher, B. Clotet, M. Floridia, J. Gerstoft, B. Hejdeman, C. Nielsen, C. Pannecouque, L. Perrin, M. F. Pirillo, L. Ruiz, J. C. Schmit, F. Schneider, A. Schoolmeester, R. Schuurman, H. J. Stellbrink, L. Stuyver, J. Van Lunzen, B. Van Remoortel, E. Van Wungaerden, S. Vella, M. Witvrouw, S. Yerly, E. De Clercq, J. Destmyer, and A. M. Vandamme. 2000. Prevalence and characteristics of multinucleoside-resistant human immunodeficiency virus type 1 among European patients receiving combinations of nucleoside analogues. Antimicrob. Agents Chemother. 44:2109-2117.
65. Whitcomb, J. M., W. Huang, K. Limoli, E. Paxinos, T. Wrin, G. Skowron, S. G. Deeks, M. Bates, N. S. Hellmann, and C. J. Petropoulos. 2002. Hypersusceptibility to non-nucleoside reverse transcriptase inhibitors in HIV-1: clinical, phenotypic and genotypic correlates. AIDS 16:F41-F47.
66. White, K. L., J. M. Chen, N. A. Margot, T. Wrin, C. J. Petropoulos, L. K. Naeger, S. Swaminathan, and M. D. Miller. 2004. Molecular mechanisms of tenofovir resistance conferred by human immunodeficiency virus type 1 reverse transcriptase containing a diserine insertion after residue 69 and multiple thymidine analog-associated mutations. Antimicrob. Agents Chemother. 48:992-1003.
67. Winters, M. A., K. L. Coolley, P. Cheng, Y. A. Girard, H. Hamdan, L. C. Kovari, and T. C. Merigan. 2000. Genotypic, phenotypic, and modeling studies of a deletion in the beta3-beta4 region of the human immunodeficiency virus type 1 reverse transcriptase gene that is associated with resistance to nucleoside reverse transcriptase inhibitors. J. Virol. 74:10707-10713.
68. Winters, M. A., K. L. Coolley, Y. A. Girard, D. J. Levee, H. Hamdan, R. W. Shafer, D. A. Katzenstein, and T. C. Merigan. 1998. A 6-basepair insert in the reverse transcriptase gene of human immunodeficiency virus type 1 confers resistance to multiple nucleoside inhibitors. J. Clin. Investig. 102:1769-1775.
69. Winters, M. A., R. M. Kagan, P. N. R. Heseltine, L. C. Kovari, and T. C. Merigan. 2005. Rare one and two amino acid inserts adjacent to codon 103 of the HIV-1 reverse transcriptase (RT) affect susceptibility to non-nucleoside RT inhibitors. Antivir. Ther. 10:363-366.
70. Winters, M. A., R. M. Kagan, P. N. R. Heseltine, and T. C. Merigan. 2005. A new 2 amino acid insertion near codon 70 of the HIV-1 protease gene. AIDS Res. Hum. Retrovir. 21:311-313.
71. Yahi, N., C. Tamalet, C. Tourres, N. Tivoli, F. Ariasi, F. Volot, J. A. Gastaut, H. Gallais, J. Moreau, and J. Fantini. 1999. Mutation patterns of the reverse transcriptase and protease genes in human immunodeficiency virus type 1-infected patients undergoing combination therapy: survey of 787 sequences. J. Clin. Microbiol. 37:4099-4106.
72. Yeni, P. G., S. M. Hammer, C. C. Carpenter, D. A. Cooper, M. A. Fischl, J. M. Gatell, B. G. Gazzard, M. S. Hirsch, D. M. Jacobsen, D. A. Katzenstein, J. S. Montaner, D. D. Richman, M. S. Saag, M. Schechter, R. T. Schooley, M. A. Thompson, S. Vella, and P. A. Volberding. 2002. Antiretroviral treatment for adult HIV infection in 2002: updated recommendations of the International AIDS Society-USA Panel. JAMA 288:222-235.
73. Zhang, Y. M., H. Imamichi, T. Imamichi, H. C. Lane, J. Falloon, M. B. Vasudevachari, and N. P. Salzman. 1997. Drug resistance during indinavir therapy is caused by mutations in the protease gene and in its Gag substrate cleavage sites. J. Virol. 71:6662-6670.